PARIS - Diatos SA and Medarex Inc. signed a licensing agreement giving Diatos exclusive European rights to develop and commercialize a potential new cancer treatment. (BioWorld International)

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 4, 2025
NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Roche looks to grow with sequencing by expansion tech
BioWorld MedTech
Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...
Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology
BioWorld
About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...